Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. - Wikidata - wikimedia - TriplyDB

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.

http://www.wikidata.org/entity/Q33573648

about

Silencing disease genes in the laboratory and the clinic Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.Deficiency of cardiac Acyl-CoA synthetase-1 induces diastolic dysfunction, but pathologic hypertrophy is reversed by rapamycin Gene and cell-mediated therapies for muscular dystrophy.Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model RNA therapeutics: beyond RNA interference and antisense oligonucleotides.Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice.Efficient in vivo manipulation of alternative pre-mRNA splicing events using antisense morpholinos in mice.Therapeutic approaches to muscular dystrophy.Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice Disruption of KATP channel expression in skeletal muscle by targeted oligonucleotide delivery promotes activity-linked thermogenesis Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping The Effects of Experimental Sleep Apnea on Cardiac and Respiratory Functions in 6 and 18 Month Old Dystrophic (mdx) Mice.Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies.Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.Progress in gene therapy of dystrophic heart disease.Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.BMPER regulates cardiomyocyte size and vessel density in vivo.Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions.Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy.Progress in therapy for Duchenne muscular dystrophy.Cell-penetrating peptides for the delivery of nucleic acids.Cardiac and respiratory dysfunction in Duchenne muscular dystrophy and the role of second messengers.New developments in the use of gene therapy to treat Duchenne muscular dystrophy.Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease.Nanotherapy for Duchenne muscular dystrophy.The heart in Duchenne muscular dystrophy: early detection of contractile performance alteration.Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice.Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.Antisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD)Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.Modeling the Transition From Decompensated to Pathological Hypertrophy.

P2860

Q29039090-94EC755C-93F9-4B8C-B4B4-8F7D0BDD5504 Q30514014-BCD91820-B3BC-448B-94CA-F7F4A1C1C445 Q33594805-AA66DC68-F8AB-415C-8CCC-B44A381E7635 Q33719493-A04AAD92-EC1E-4F56-9F6B-2F073EFCBB8D Q33831193-6F17B1B7-B78E-4C8D-A038-7FF3E7CA4400 Q34117470-F6135049-B547-41D2-A1F1-DA2D8DCB80CC Q34248493-170EF9E0-DBC8-4160-9A02-6B1CA87DC41D Q34279254-B869D867-ECE4-41E8-A55A-5C1C5FFCA580 Q34508301-5C568912-B4B5-4BAB-8E35-14285C56F45F Q34556906-6FFCD07F-7D1E-4384-8BCD-49DEBBE6B5D9 Q34675818-764F0CCB-FAA3-4CAC-8417-9C7DD8825F78 Q34982869-8F5C1077-C8B5-4997-BD70-8B10BF684E8B Q35133936-C87CF966-D5B5-46F7-A54F-E02FB813AE30 Q35399258-73CF02B4-204B-4E04-AD00-F437FC297A64 Q35802092-D27DDEF5-8989-4F8F-B77A-945A0A3C5044 Q35903669-FB163DA0-4DE7-46AA-A6B5-998328699333 Q35924068-CAB59348-11E0-45A4-AFCF-420EF43A8203 Q36297940-3BD70DA3-D144-495F-AA56-8B27826B7C6A Q36773242-C1199E58-3568-4474-A936-4F86B08B6C79 Q36925191-4C1D6003-79E2-443B-8CDE-7C135505B78C Q37021623-AA599F6A-B21B-4B7E-98AE-0C4E60B5C593 Q37265279-5CE9928F-A3C9-487E-92F1-14104AB060EA Q37889770-E82615C9-535A-444A-9C6E-922CF976B0B3 Q37907407-ED6255F6-B8DD-40A7-BD7B-72CE80FC47F2 Q37908904-F76793CD-8273-4412-B091-01407024B2D7 Q38010767-B5BC722A-D1B3-406F-85F8-FC5D5E30B9A8 Q38103213-BE565289-46B6-4FAE-BF31-12A30FBA5F6F Q38168863-F87526E4-5E14-46A2-B063-3B68577EC3EB Q38177946-F8EAEC00-B7D4-452F-97DD-D0536E59103A Q39233936-C5FEA02C-C479-4C8D-940F-F18D585A5C6B Q39529041-E2018DF3-9284-4F82-B179-650D1309879F Q41854668-F5F370F5-F3DD-4B78-8192-DC3B642054AC Q41890992-304F3365-A692-401A-9BE5-24FCFA890795 Q42122236-CB83BA97-2CD7-46D8-9D18-C56D56775D8C Q55309190-592F7447-423F-4EBB-AD16-E1CD35ADFA7F Q55424297-1495547D-93AC-4836-A70E-AE30B4E14E9B

P2860

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.

http://www.wikidata.org/entity/Q33573648

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Long-term improvement in mdx c ...... njugated morpholino oligomers.

@ast

Long-term improvement in mdx c ...... njugated morpholino oligomers.

@en

Long-term improvement in mdx c ...... njugated morpholino oligomers.

@nl

type

label

Long-term improvement in mdx c ...... njugated morpholino oligomers.

@ast

Long-term improvement in mdx c ...... njugated morpholino oligomers.

@en

Long-term improvement in mdx c ...... njugated morpholino oligomers.

@nl

prefLabel

Long-term improvement in mdx c ...... njugated morpholino oligomers.

@ast

Long-term improvement in mdx c ...... njugated morpholino oligomers.

@en

Long-term improvement in mdx c ...... njugated morpholino oligomers.

@nl

P1433

Q33573648-413ABC9E-8EDD-4621-9E93-47D1ED5F1245

P1476

Q33573648-6223FB55-47F6-477C-A108-ABD4362E00D5

P2093

Q33573648-062B0450-A268-4023-A1A3-576D2285B452

Q33573648-CCDB830D-77E8-4E70-B41D-56CC92F49D8A

Q33573648-E6E1B112-1821-41B9-B768-5A8E6148706C

P2860

Q33573648-00DE8DEA-F120-4EAE-A106-4C11CCB16E1A

Q33573648-0483605F-A1D0-4524-9AE6-36B973A7115D

Q33573648-079A079F-3CC6-4E03-949E-F674611D2B7B

Q33573648-187F9353-9E12-48CC-9142-9354DB5D8BBB

Q33573648-1BC356E0-E9B6-4254-99C0-5C1414924530

Q33573648-2995C1F5-051F-4325-9E59-0931C2A6F0AC

Q33573648-29A77B52-CFE8-4B53-BD6B-747DEE9742EA

Q33573648-2A740D07-7A30-41B1-A311-598953E4979F

Q33573648-2C2D302F-F216-4390-9367-FF99CAAFCAE9

Q33573648-367D57EF-5401-4F4A-82E9-B84378C99266

P304

Q33573648-BF7803F5-A7A2-48F9-B78A-39826CAB80B0

P31

Q33573648-1712BC58-3972-496B-B8D2-A1142EB5EB51

P356

Q33573648-43A08680-4EFC-4C56-BC37-D336AF00EF52

P433

Q33573648-4D29C43A-A5C8-4996-B0F8-19D5E0713C4C

P478

Q33573648-85979DD4-F2A8-463B-9DB3-3652AF95B2C2

P50

Q33573648-760E1898-7C19-45F4-B69A-DA19756A4DA3

Q33573648-D4353C09-CCBD-4E6E-A521-CD6E4E353D5E

P577

Q33573648-DFE85538-580A-4072-AEDD-BA2EC4F13300

P5875

Q33573648-1C8721B0-5A08-4866-B2CE-7DDDB021A51A

P698

Q33573648-6C2111E9-02F7-4FFC-9FBF-2A87BA3DA714

P932

Q33573648-5AAC6E47-EC43-44F0-8719-467B53042C16

P356

P1433

Cardiovascular Research

P1476

Long-term improvement in mdx c ...... njugated morpholino oligomers.

@en

P2093

Hong M Moulton

http://www.w3.org/2001/XMLSchema#string

Natee Jearawiriyapaisarn

http://www.w3.org/2001/XMLSchema#string

Peter Sazani

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance

Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity

Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles

Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.

Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.

Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.

Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides.

Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model.

Gene therapy progress and prospects: Duchenne muscular dystrophy.

Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.

P304

444-453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CVR/CVP335

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26881542

http://www.w3.org/2001/XMLSchema#string

P698

19815563

http://www.w3.org/2001/XMLSchema#string

P932

2802205

http://www.w3.org/2001/XMLSchema#string